620 related articles for article (PubMed ID: 15946907)
1. SOST is a target gene for PTH in bone.
Keller H; Kneissel M
Bone; 2005 Aug; 37(2):148-58. PubMed ID: 15946907
[TBL] [Abstract][Full Text] [Related]
2. In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene.
Onyia JE; Miles RR; Yang X; Halladay DL; Hale J; Glasebrook A; McClure D; Seno G; Churgay L; Chandrasekhar S; Martin TJ
J Bone Miner Res; 2000 May; 15(5):863-71. PubMed ID: 10804015
[TBL] [Abstract][Full Text] [Related]
3. Control of the SOST bone enhancer by PTH using MEF2 transcription factors.
Leupin O; Kramer I; Collette NM; Loots GG; Natt F; Kneissel M; Keller H
J Bone Miner Res; 2007 Dec; 22(12):1957-67. PubMed ID: 17696759
[TBL] [Abstract][Full Text] [Related]
4. Parathyroid hormone induces receptor activity modifying protein-3 (RAMP3) expression primarily via 3',5'-cyclic adenosine monophosphate signaling in osteoblasts.
Phelps E; Bezouglaia O; Tetradis S; Nervina JM
Calcif Tissue Int; 2005 Aug; 77(2):96-103. PubMed ID: 16075364
[TBL] [Abstract][Full Text] [Related]
5. Intermittent parathyroid hormone (PTH) treatment and age-dependent effects on rat cancellous bone and mineral metabolism.
Friedl G; Turner RT; Evans GL; Dobnig H
J Orthop Res; 2007 Nov; 25(11):1454-64. PubMed ID: 17557320
[TBL] [Abstract][Full Text] [Related]
6. Identification of a PTH regulated gene selectively induced in vivo during PTH-mediated bone formation.
Robinson JA; Susulic V; Liu YB; Taylor C; Hardenburg J; Gironda V; Zhao W; Kharode Y; McLarney S; Bai Y; Malone DP; Murrills R; Bex F
J Cell Biochem; 2006 Aug; 98(5):1203-20. PubMed ID: 16514668
[TBL] [Abstract][Full Text] [Related]
7. Does osteocytic SOST suppression mediate PTH bone anabolism?
Kramer I; Keller H; Leupin O; Kneissel M
Trends Endocrinol Metab; 2010 Apr; 21(4):237-44. PubMed ID: 20074973
[TBL] [Abstract][Full Text] [Related]
8. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis.
Bellido T; Ali AA; Gubrij I; Plotkin LI; Fu Q; O'Brien CA; Manolagas SC; Jilka RL
Endocrinology; 2005 Nov; 146(11):4577-83. PubMed ID: 16081646
[TBL] [Abstract][Full Text] [Related]
9. Parathyroid hormone fragments may stimulate bone growth in ovariectomized rats by activating adenylyl cyclase.
Rixon RH; Whitfield JF; Gagnon L; Isaacs RJ; Maclean S; Chakravarthy B; Durkin JP; Neugebauer W; Ross V; Sung W
J Bone Miner Res; 1994 Aug; 9(8):1179-89. PubMed ID: 7976500
[TBL] [Abstract][Full Text] [Related]
10. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation.
van Bezooijen RL; ten Dijke P; Papapoulos SE; Löwik CW
Cytokine Growth Factor Rev; 2005 Jun; 16(3):319-27. PubMed ID: 15869900
[TBL] [Abstract][Full Text] [Related]
11. An intact N terminus is required for the anabolic action of parathyroid hormone on adult female rats.
Armamento-Villareal R; Ziambaras K; Abbasi-Jarhomi SH; Dimarogonas A; Halstead L; Fausto A; Avioli LV; Civitelli R
J Bone Miner Res; 1997 Mar; 12(3):384-92. PubMed ID: 9076581
[TBL] [Abstract][Full Text] [Related]
12. Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells.
Ishizuya T; Yokose S; Hori M; Noda T; Suda T; Yoshiki S; Yamaguchi A
J Clin Invest; 1997 Jun; 99(12):2961-70. PubMed ID: 9185520
[TBL] [Abstract][Full Text] [Related]
13. Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1.
Bodine PV; Seestaller-Wehr L; Kharode YP; Bex FJ; Komm BS
J Cell Physiol; 2007 Feb; 210(2):352-7. PubMed ID: 17044082
[TBL] [Abstract][Full Text] [Related]
14. Bone morphogenetic proteins and their antagonists: the sclerostin paradigm.
van Bezooijen RL; Papapoulos SE; Löwik CW
J Endocrinol Invest; 2005; 28(8 Suppl):15-7. PubMed ID: 16323824
[TBL] [Abstract][Full Text] [Related]
15. Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity.
Iida-Klein A; Lu SS; Cosman F; Lindsay R; Dempster DW
Bone; 2007 Feb; 40(2):391-8. PubMed ID: 17056311
[TBL] [Abstract][Full Text] [Related]
16. Systemic bone formation with weekly PTH administration in ovariectomized rats.
Gittens SA; Wohl GR; Zernicke RF; Matyas JR; Morley P; Uludag H
J Pharm Pharm Sci; 2004 Jan; 7(1):27-37. PubMed ID: 15144732
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of SOST/sclerostin by PTH: a novel mechanism of hormonal control of bone formation mediated by osteocytes.
Bellido T
J Musculoskelet Neuronal Interact; 2006; 6(4):358-9. PubMed ID: 17185824
[No Abstract] [Full Text] [Related]
18. Effects of parathyroid hormone on Wnt signaling pathway in bone.
Kulkarni NH; Halladay DL; Miles RR; Gilbert LM; Frolik CA; Galvin RJ; Martin TJ; Gillespie MT; Onyia JE
J Cell Biochem; 2005 Aug; 95(6):1178-90. PubMed ID: 15962290
[TBL] [Abstract][Full Text] [Related]
19. The role of protein kinase C-delta in PTH stimulation of IGF-binding protein-5 mRNA in UMR-106-01 cells.
Erclik MS; Mitchell J
Am J Physiol Endocrinol Metab; 2002 Mar; 282(3):E534-41. PubMed ID: 11832354
[TBL] [Abstract][Full Text] [Related]
20. Changes in osteoblast, chondrocyte, and adipocyte lineages mediate the bone anabolic actions of PTH and small molecule GSK-3 inhibitor.
Kulkarni NH; Wei T; Kumar A; Dow ER; Stewart TR; Shou J; N'cho M; Sterchi DL; Gitter BD; Higgs RE; Halladay DL; Engler TA; Martin TJ; Bryant HU; Ma YL; Onyia JE
J Cell Biochem; 2007 Dec; 102(6):1504-18. PubMed ID: 17520664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
